ACADIA Pharmaceuticals Inc. Free Cash Flow

Free Cash Flow of ACAD for past 10 years: annual, quarterly and twelve month trailing (TTM) including Free Cash Flow growth rates and interactive chart. Free cash flowis calculated as operating cash flow minus of capital expenditures. Interest payments are excluded from the generally accepted definition of free cash flow. Free cash flow is the cash flow available to all the investors in a company, including common stockholders, preferred shareholders, and lenders. Some investors prefer FCF or FCF per share over earnings and earnings per share as a measure of profitability. However, because FCF accounts for investments in property, plant, and equipment it can be lumpy over time. Free cash flow is usually used in discounted cash flow models to determine a company's intrinsic value.


Highlights and Quick Summary

  • Free Cash Flow for the quarter ending December 30, 2020 was $-28.3 Million (a 14.18% increase compared to previous quarter)
  • Year-over-year quarterly Free Cash Flow decreased by -42.91%
  • Annual Free Cash Flow for 2020 was $-142 Million (a -5.18% decrease from previous year)
  • Annual Free Cash Flow for 2019 was $-150 Million (a -11.7% decrease from previous year)
  • Annual Free Cash Flow for 2018 was $-170 Million (a -22.42% decrease from previous year)
  • Twelve month Free Cash Flow ending December 30, 2020 was $-142 Million (a -0.81% decrease compared to previous quarter)
  • Twelve month trailing Free Cash Flow increased by 4.1% year-over-year
Trailing Free Cash Flow for the last four month:
30 Dec '20 29 Sep '20 29 Jun '20 30 Mar '20
$-142 Million $-143 Million $-137 Million $-136 Million
Visit stockrow.com/ACAD for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Free Cash Flow of ACADIA Pharmaceuticals Inc.

Most recent Free Cash Flowof ACAD including historical data for past 10 years.

Interactive Chart of Free Cash Flow of ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. Free Cash Flow for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $-28.31 $-24.79 $-39.31 $-49.58 $-141.98
2019 $-29.47 $-18.93 $-38.42 $-65.0 $-149.74
2018 $-39.61 $-43.29 $-40.99 $-45.68 $-169.57
2017 $-29.9 $-58.46 $-59.16 $-71.05 $-218.57
2016 $-61.44 $-49.73 $-65.33 $-41.42 $-217.91
2015 $-35.02 $-32.04 $-30.55 $-26.33 $-123.94
2014 $-17.9 $-17.56 $-16.97 $-14.19 $-66.61
2013 $-10.39 $-9.89 $-5.52 $-6.58 $-32.38
2012 $-6.3 $-5.16 $-4.71 $-5.22 $-21.38
2011 $-5.34 $-4.18 $-5.28 $-5.11 $-19.9
2010 $4.6 $-2.52 $-6.21 $-10.58

Business Profile of ACADIA Pharmaceuticals Inc.

Sector: Healthcare
Industry: Biotechnology
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.